Gabrielle Heilek‐Snyder

A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance Mechanism

Monique Nijhuis, Noortje M. van Maarseveen, Stéphane Lastère et al. · PLoS Medicine · 2007 · 167 citations · Full text

Life Sciences, Infectious Diseases, Molecular Genetics +17

HIV‐1 Coreceptor Use in Triple‐Class Treatment–Experienced Patients: Baseline Prevalence, Correlates, and Relationship to Enfuvirtide Response

Tom Melby, Michael DeSpirito, Ralph DeMasi et al. · The Journal of Infectious Diseases · 2006 · 112 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Characterization of Envelope Glycoprotein gp41 Genotype and Phenotypic Susceptibility to Enfuvirtide at Baseline and on Treatment in the Phase III Clinical Trials TORO-1 and TORO-2

Thomas Melby, Prakash Sista, Ralph DeMasi et al. · AIDS Research and Human Retroviruses · 2006 · 66 citations

Life Sciences, Infectious Diseases, Pharmacotherapy +17

Substrate Envelope and Drug Resistance: Crystal Structure of RO1 in Complex with Wild-Type Human Immunodeficiency Virus Type 1 Protease

M. Prabu-Jeyabalan, Nancy M. P. King, E.A. Nalivaika et al. · Antimicrobial Agents and Chemotherapy · 2006 · 36 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +17

Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro

Chun‐Kuei Su, Tom Melby, Ralph DeMasi et al. · Journal of Clinical Virology · 2006 · 29 citations

Life Sciences, Pharmacokinetics, Pharmacology +16